BTIG analyst Mark Massaro raised the firm’s price target on Guardant Health (GH) to $80 from $70 and keeps a Buy rating on the shares after the company’s analyst day. The firm raised its average selling price assumptions and also raised its FY28 revenue target by $200M, the analyst tells investors in a research note. BTIG adds that investor sentiment on this stock continues to grow, and there are quite a number of important catalysts that will “propel this growth engine to hum for years”.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $67 from $56 at Guggenheim
- Guardant Health price target raised to $70 from $65 at Mizuho
- Guardant Health’s Strong Growth Trajectory and Unique Oncology Approach Earns Buy Rating
- Wolfe upgrades Guardant to Outperform after ‘solid’ analyst day
- Guardant Health price target raised to $70 from $60 at JPMorgan